McCann FitzGerald advises Novo Nordisk on its Acquisition of U.S. and Canadian Rights to Macrilen from Strongbridge Biopharma

McCann FitzGerald is advising Novo Nordisk on its $145 million acquisition of the U.S. and Canadian rights to Macrilen from Strongbridge Biopharma plc. Novo Nordisk will also acquire newly issued Strongbridge shares representing approximately 10% of the outstanding shares of Strongbridge in an investment of approximately $37 million. The transaction, which is expected to close in December 2018, is subject to regulatory approval.

Filter by: